Physician profile
Melody Burton
NPI 1982667093
$4,223.94
in general payments reported to CMS, 2019-2025
27 companies · $597 in 2025
The $597 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $381 · 2021: $696 · 2022: $695 · 2023: $710 · 2024: $836 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $685.71 | 2021-2025 | Azstarys |
| Tris Pharma INC | $634.19 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Kaleo, INC. | $372.79 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $303.06 | 2019-2025 | |
| Cranial Technologies, INC | $288.23 | 2019-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $261.89 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $224.51 | 2021-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $208.95 | 2022-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $204.49 | 2020-2022 | |
| Sanofi Pasteur INC. | $195.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $174.00 | 2022-2025 | Bexsero, Boostrix |
| Adlon Therapeutics L.P. | $168.36 | 2020-2021 | |
| Sobi, INC | $66.44 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $66.27 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $57.28 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $46.26 | 2021-2025 | Immunocap |
| Genentech USA, INC. | $43.93 | 2020-2022 | |
| Alk-Abello, INC | $36.83 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $29.31 | 2023 | |
| Abbott Laboratories | $29.15 | 2025 | Id Now Instrument |
| Verrica Pharmaceuticals INC. | $27.96 | 2024-2025 | Ycanth |
| Medline Industries Lp | $20.99 | 2019 | |
| Shire North American Group INC | $19.42 | 2019 | |
| Seqirus USA INC | $16.49 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.19 | 2025 | Zoryve |
| Mission Pharmacal Company | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.